Mentions
Extended reach
Total likes
Video views
AI synopsis
The discussions frequently highlight the impressive efficacy of tirzepatide, with comments noting a '90% prevention or reversal of diabetes' and mentioning specific data points like a hazard ratio of '0.07'. The enthusiastic tone, use of phrases like 'wow!' and 'substantial and sustained weight reduction', along with frequent citations from the research itself, reflect both excitement and a clear understanding of the drug's impact.
The overwhelming majority of discussions reflect strong support for the findings and implications of the study.
Participants express high levels of curiosity about the potential of tirzepatide in treating obesity and preventing diabetes.
While several posts reference potential issues and data points, many participants offer only brief mentions rather than deep analyses.
Many contributors underscore the substantial implications for diabetes prevention and obesity treatment, highlighting a belief in its transformative potential.
Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocrinology https://t.co/OlUSvWdJ0T
Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a lower risk (HR: 0.12) of progression to type 2 DM" @NEJM https://t.co/xdYFMjiasm https://t.co/T9HC30eFKZ
(419/347) #論文マラソン マンジャロは肥満者にとって糖尿病予防になるか？ 肥満者2539名に対して、マンジャロ5, 10, 15mgorプラセボに割り付け。３年間追跡 マンジャロはプラセボより糖尿病発症が少なかった(HR:0.07) https://t.co/lkMS1DEc5e
【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -19.7％ プラセボ -1.3％ 2型糖尿病発症リスクは1.3％ vs 13.3％と93%減少 https://t.co/bUPMoh8APP https://t.co/WliBeynaRQ
Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv 5. https://t.co/TKT3xJbcDF 6. https://t.co/LCPGEEwcVZ 7. https://t.co/IazDTzuRuz 8. https://t.co/JS85pKMfaW 9. https://t.co/wdrTn03WYv 10.
New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo AAV9.LAMP2B Gene Therapy in Danon Disease https://t.co/2EzWA3JLj0
Tirzepatide is a treatment option showing effective weight loss in obesity. This podcast focuses on its role in reducing type 2 diabetes incidence and discusses recent findings on AF screening and related cardiology…
This video delves into advanced concepts in quantum physics. It covers the fundamental principles that govern quantum mechanics and their practical applications in modern technology. Gain insights into phenomena such as…
Today, we discuss Tirzepatide, a medication used for obesity and diabetes. It offers promising results by affecting appetite regulation and promoting weight loss, supported by recent clinical research and systematic…
Tirzepatide for Obesity Treatment and Diabetes Prevention Via @NEJM https://t.co/FXul4RUWJC
RT @EricTopol: New @NEJM A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs pla…
RT @MariosGeorgakis: Hazard ratio=0.07❗️ That's the ridiculous effect of tirzepatide (dual GIP/GLP1r agonist) on the 3-year incidence of d…
RT @MariosGeorgakis: Hazard ratio=0.07❗️ That's the ridiculous effect of tirzepatide (dual GIP/GLP1r agonist) on the 3-year incidence of d…
RT @a_fisiolog57853: CARTA AL EDITOR QUE SE SUMA A LAS INQUIETUDES PLANTEADAS POR GIAN PAOLO FADINI https://t.co/bBz3VEhIaN https://t.co/…
CARTA AL EDITOR QUE SE SUMA A LAS INQUIETUDES PLANTEADAS POR GIAN PAOLO FADINI https://t.co/bBz3VEhIaN https://t.co/Sm0y6zn2AF Y un humilde servidor: https://t.co/F8GfszAROD https://t.co/mxF1N0pWiR
Referências: Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., et al (2025). Tirzepatide for Obesity Treatment and Diabetes Prevention. The New England journal of medicine, 392(10), 958–971. https://t.co/aIoFfMdHAL
RT @DrMAlAteeq: النتائج : - نقص للوزن بدرجات كبيرة( حتى 20%) - الابتعاد عن مرحلة ما قبل السكري - أعراض جانبية محتملة في الجهاز الهضمي - لم…
RT @DrSamuelBHume: Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv…
לא צריך להיות מדען מובהק כדי לראות את האפקט המרשים של התרופה תירזפאטיד ( שם מסחרי מונג'ארו) בשלשה מינונים ( סהכ 762 מטופלים),עולים מול קבוצת ביקורת (270) לירידה במשקל לאחר הטיפול, במשך הטיפול של 176 שבועות, והיארעות סכרת מטיפוס 2. https://t.co/LpuawQLcrQ https://t.co/ZxYC7hCPEk
RT @DrSamuelBHume: Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv…
Sources: 1. https://t.co/l9DEd32Ygr 2. https://t.co/dSQKFOalij 3. https://t.co/kJ6Pacs7cc 4. https://t.co/06205mi6Sv 5. https://t.co/TKT3xJbcDF 6. https://t.co/LCPGEEwcVZ 7. https://t.co/IazDTzuRuz 8. https://t.co/JS85pKMfaW 9. https://t.co/wdrTn03WYv 10.
@fc_dbnk @cpa4990 チルゼパチド10mgの方が強い減量効果が認められるというエビデンスはありますhttps://t.co/3zgLmqAJ7W https://t.co/CiTTQE6qks
Tirzepatida para tratamiento de la obesidad y prevención de la diabetes https://t.co/D4F5xrao7H PMID 39536238
RT @docramiro: Tirzepatida para el manejo de diabetes tipo 2 y obesidad Referencia: DOI: 10.1056/NEJMoa2410819 https://t.co/yJkVhWJP4I
チルゼパチド（マンジャロ®）で肥満治療と糖尿病予防？ DOI: 10.1056/NEJMoa2410819 プラセボ群と比較して、体重減少と2型糖尿病の発生率が有意に低かったと報告されました リミテーションとしては、離脱率が高く、被験者の4人に3人が白人だったようです https://t.co/yJCl2tYexY
Should we be prescribing GLP1 receptor agonists in pre-diabetes + overweight? You certainly will substantially reduce the lifetime risk of diabetes as data from SURMOUNT trial demonstrates. But, the $ Cost of treatment and duration remains in question. https://t.co/NaWjl9gngm https://t.co/CNnZL1nCEA
RT @agingdoc1: Tirzepatide for Obesity Treatment and Diabetes Prevention https://t.co/kthYffr266 https://t.co/E0T5xrXO51
Tirzepatide for Obesity Treatment and Diabetes Prevention https://t.co/kthYffr266 https://t.co/E0T5xrXO51
RT @BITNavarra: Tirzepatida para el tratamiento de la obesidad en pacientes con pre-diabetes (New England Journal of Medicine) Reducción d…
RT @docramiro: Tirzepatida para el manejo de diabetes tipo 2 y obesidad Referencia: DOI: 10.1056/NEJMoa2410819 https://t.co/yJkVhWJP4I
Tirzepatide significantly reduced weight and diabetes risk in obese patients over three years compared to placebo. by Jastreboff AM, le Roux CW (...) Jouravskaya I et 10 al. in N Engl J Med #MedSky
Tirzepatide significantly reduced weight and diabetes risk in obese patients over three years compared to placebo. by Jastreboff AM, le Roux CW (...) Jouravskaya I et 10 al. in N Engl J Med https://t.co/yJGQj7j911 #MedX #MedResearch
Today's MedBeats: Tirzepatide for Obesity Treatment and Diabetes Prevention #Nephrology #InternalMedicine https://t.co/VHxm8thxvP
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/S5l4XCAqY5
RT @BagaiDr: Tirzepatide for Obesity Treatment and Diabetes Prevention.NEJM; At 176 weeks, mean percent change in body weight who received…
Tirzepatide for Obesity Treatment and Diabetes Prevention.NEJM; At 176 weeks, mean percent change in body weight who received tirzepatide was −12.3% with 5-mg dose, −18.7% with 10-mg dose, −19.7% with 15-mg dose, vs −1.3% who received placebo (P<0.001) https://t.co/oCqQfavMgI
A 3-year study of tirzepatide in participants with #obesity and prediabetes showed substantial and sustained weight reduction and decreased risk of progression to diabetes with tirzepatide, as compared with placebo. Full SURMOUNT-1 trial results: nej.md/48VdDZp #MedSky #EndoSky
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
GLP1はもはや0次予防薬？！Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/WfwIwNQzim
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
Tirzepatide for Obesity Treatment and Diabetes Prevention https://t.co/yOmYC5vESR
【DrゆみのWeekly Journal Scan】 ＊肥満と糖尿病へのGIP/GLP-1RAの長期効果 from NEJM＊ https://t.co/TAjYwgLKS0
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
Referans: Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 6;392(10):958-971.
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/2hnWWSLQO7
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes https://t.co/kCuzCCJp7X https://t.co/AaWw6jQQc3
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
RT @NEJM: Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocri…
Original Article: Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo #Endocrinology https://t.co/OlUSvWdJ0T
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
Robertfleming1@nhs.net https://t.co/7P8LiNT4uG
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
Holy shit! > 90 % prevention or reversal of diabetes Other than vaccines and systemic anticoagulants, I’ve never seen data like this before for diabetes or cardio metabolic diseases https://t.co/M5ucDjTUsd
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @BITNavarra: Tirzepatida para el tratamiento de la obesidad en pacientes con pre-diabetes (New England Journal of Medicine) Reducción d…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
Tirzepatide: 3-year study shows effective in reducing weight and delaying type 2 diabetes in obesity & prediabetes. Significant findings from the SURMOUNT-1 trial! #ObesityScience PMID:39536238, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2410819 #Medsky
Tirzepatide: 3-year study shows effective in reducing weight and delaying type 2 diabetes in obesity & prediabetes. Significant findings from the SURMOUNT-1 trial! #ObesityScience PMID:39536238, N Engl J Med 2025, @NEJM https://t.co/NSmXraKvYV #MedX #PharmaX
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/5TW9pgLaaB
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @BITNavarra: Tirzepatida para el tratamiento de la obesidad en pacientes con pre-diabetes (New England Journal of Medicine) Reducción d…
RT @BITNavarra: Tirzepatida para el tratamiento de la obesidad en pacientes con pre-diabetes (New England Journal of Medicine) Reducción d…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @drbennisahmed: Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obe…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
Tirzepatida para el tratamiento de la obesidad en pacientes con pre-diabetes (New England Journal of Medicine) Reducción de peso y menor riesgo de progresión a DM2 comparado con placebo https://t.co/BhuOjKEhlg
Tirzepatide for Obesity Treatment and Diabetes Prevention Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes https://t.co/kCuzCCJp7X https://t.co/FATTLWQdJJ
RT @NEJM: New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa…
New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) nej.md/3QJIVKn Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) nej.md/48VdDZp AAV9.LAMP2B Gene Therapy in Danon Disease (phase 1 study) nej.md/40IBJVh #MedSky
New in the March 6, 2025, issue of NEJM: Male-Partner Treatment and Bacterial Vaginosis (StepUp trial) https://t.co/pfv4t6uPTa Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 trial) https://t.co/5TTgJfbKyo AAV9.LAMP2B Gene Therapy in Danon Disease https://t.co/2EzWA3JLj0
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/Sk1jC1GDf0
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
"Tirzepatide for Obesity Treatment and Diabetes Prevention." Étude SURMOUNT-1. Publié ce jour dans le @nejm.org #MedSky #EndoSky #Obesity www.nejm.org/doi/full/10....
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/2GqI1VXhHp #tirzepatide @FundacionLilly @SpainLilly4016
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
RT @acorderofort: Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and pred…
Tirzepatide for Obesity Treatment and Diabetes Prevention "3y treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a lower risk (HR: 0.12) of progression to type 2 DM" @NEJM https://t.co/xdYFMjiasm https://t.co/T9HC30eFKZ
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/CnxPXH5n6S
Tirzepatide for Obesity Treatment and Diabetes Prevention メディカルダイエットに成功し、身体が軽くなったのでトレラン野郎になってメチャ健康的に過ごしている方に数年ぶりにお会いした 人生変えるキッカケになれば、治療を続ける必要はない https://t.co/P7Aao7PszF
Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/GQyKphPehc
RT @Obesidades_mx: @ConscienHealth -Wang L, et al. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients…
@ConscienHealth -Wang L, et al. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024. -Jastreboff AM, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2024.
RT @saip_pydi: Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/Sk1jC1GDf0
RT @saip_pydi: Tirzepatide for Obesity Treatment and Diabetes Prevention | New England Journal of Medicine https://t.co/Sk1jC1GDf0
Tirzepatide for Obesity Treatment and Diabetes Prevention - PubMed https://t.co/p8hxQq1Gvo
New Publication! Explore the latest science in #Obesity from the SURMOUNT-1 Phase 3 trial, now available in the New England Journal of Medicine. Read the results in NEJM: https://t.co/tFB4tXtqY2 https://t.co/o4nsZyg0GW
New Publication! Explore the latest science in #Obesity from the SURMOUNT-1 Phase 3 trial, now available in the New England Journal of Medicine. Read the results in NEJM: https://t.co/tFB4tXtqY2
This month, a phase 3 trial of tirzepatide (a GLP-1 drug) found that it reduced the chances of developing type 2 diabetes by around 90% (!), among people with obesity and pre-diabetes. Tirzepatide for Obesity Treatment and Diabetes Prevention www.nejm.org/doi/full/10....
RT @Pon_yurublog: 肥満症患者へのチルゼパチドの抗肥満＆糖尿病予防効果を調べたNEJMの論文 ☑︎ なんと20%も体重を低下させた ☑︎ 糖尿病発症リスクは17週で0.12、176週で0.07倍と素晴らしい結果 https://t.co/s5lFWkmGhp
RT @Pon_yurublog: 肥満症患者へのチルゼパチドの抗肥満＆糖尿病予防効果を調べたNEJMの論文 ☑︎ なんと20%も体重を低下させた ☑︎ 糖尿病発症リスクは17週で0.12、176週で0.07倍と素晴らしい結果 https://t.co/s5lFWkmGhp
肥満症患者へのチルゼパチドの抗肥満＆糖尿病予防効果を調べたNEJMの論文 ☑︎ なんと20%も体重を低下させた ☑︎ 糖尿病発症リスクは17週で0.12、176週で0.07倍と素晴らしい結果 https://t.co/s5lFWkmGhp
RT @STITCHESMed: Tirzepatide over three years significantly reduced weight and type 2 diabetes risk in individuals with obesity and prediab…
https://t.co/Zlekq4rIhG
Tirzepatide over three years significantly reduced weight and type 2 diabetes risk in individuals with obesity and prediabetes versus placebo. by Jastreboff AM, le Roux CW (...) Jouravskaya I et 10 al. in N Engl J Med
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @redGDPS:
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
RT @dr_ukio: 【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -1…
【チルゼパチドが糖尿病発症を93%抑制（NEJM)】 SURMOUNT-1試験のうち 肥満症＋糖尿病予備群の1032人3年間介入 平均BMI 38.8 176週時の体重変化率 チルゼパチド5mg -12.3％、10mg -18.7％、15mg -19.7％ プラセボ -1.3％ 2型糖尿病発症リスクは1.3％ vs 13.3％と93%減少 https://t.co/bUPMoh8APP https://t.co/WliBeynaRQ
RT @muscle_penguin_: (419/347) #論文マラソン マンジャロは肥満者にとって糖尿病予防になるか？ 肥満者2539名に対して、マンジャロ5, 10, 15mgorプラセボに割り付け。３年間追跡 マンジャロはプラセボより糖尿病発症が少なかった(HR:…
RT @muscle_penguin_: (419/347) #論文マラソン マンジャロは肥満者にとって糖尿病予防になるか？ 肥満者2539名に対して、マンジャロ5, 10, 15mgorプラセボに割り付け。３年間追跡 マンジャロはプラセボより糖尿病発症が少なかった(HR:…
(419/347) #論文マラソン マンジャロは肥満者にとって糖尿病予防になるか？ 肥満者2539名に対して、マンジャロ5, 10, 15mgorプラセボに割り付け。３年間追跡 マンジャロはプラセボより糖尿病発症が少なかった(HR:0.07) https://t.co/lkMS1DEc5e
Wow! Hazard ratio of 0.07 -Tirzepatide for Obesity Treatment and Diabetes Prevention www.nejm.org/doi/full/10....
#Tirzepatide for #Obesity Treatment and Diabetes Prevention @carel_leroux @NEJM https://t.co/rdtb3TnuPI
Tirzepatide for Obesity Treatment and Diabetes Prevention - SURMOUNT trial. www.nejm.org/doi/full/10....